Keith Dlugolenski

Discovery of the Potent and Selective M1 PAM-Agonist<i>N</i>-[(3<i>R</i>,4<i>S</i>)-3-Hydroxytetrahydro-2<i>H</i>-pyran-4-yl]-5-methyl-4-[4-(1,3-thiazol-4-yl)benzyl]pyridine-2-carboxamide (PF-06767832): Evaluation of Efficacy and Cholinergic Side Effects

Jennifer E. Davoren, Che‐Wah Lee, Michelle R. Garnsey et al. · Journal of Medicinal Chemistry · 2016 · 83 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +17

Discovery and Lead Optimization of Atropisomer D1 Agonists with Reduced Desensitization

Jennifer E. Davoren, Deane M. Nason, Jotham W. Coe et al. · Journal of Medicinal Chemistry · 2018 · 51 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +17

Design and optimization of selective azaindole amide M1 positive allosteric modulators

Jennifer E. Davoren, Steven V. O’Neil, Dennis P. Anderson et al. · Bioorganic & Medicinal Chemistry Letters · 2015 · 44 citations · Full text

Pharmacy, Medicinal Chemistry, Drug Design +13

Pharmacological disruption of mouse social approach behavior: Relevance to negative symptoms of schizophrenia

Ashley N. Hanks, Keith Dlugolenski, Zoë A. Hughes et al. · Behavioural Brain Research · 2013 · 37 citations

Medicine, Neuroscience, Pharmacology +13

Characterization of PF-6142, a Novel, Non-Catecholamine Dopamine Receptor D1 Agonist, in Murine and Nonhuman Primate Models of Dopaminergic Activation

Rouba Kozak, Tamás Kiss, Keith Dlugolenski et al. · Frontiers in Pharmacology · 2020 · 25 citations · Full text

Medicine, Neuroscience, Pharmacology +16